Showing 2571-2580 of 2812 results for "".
- Nestle to Explore Strategic Options for Skin Health Divisionhttps://modernaesthetics.com/news/nestle-to-explore-strategic-options-for-skin-health-division/2472031/...After further analysis and consideration, the Board has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group’s strategic scope
- Special Report: Behind Allergan's and Bonti's Headline-Making Dealhttps://modernaesthetics.com/news/special-report-behind-allergans-and-bontis-headline-making-deal/2472032/The race was on. After years of dormancy in the neuromodulator category, at least three novel toxins— Evolus’ DWP-450, Revance’s daxibotulinumtoxinA, and Bonti’s EB-001—were coming down the pike. Industry watchers were abuzz with predictions about which toxin
- Allergan Acquires Bonti for $195Mhttps://modernaesthetics.com/news/allergan-acquires-bonti-for-195m/2472036/Allergan acquired Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the
- Thermi Debuts Arvati Platformhttps://modernaesthetics.com/news/themi-debuts-arvati-platform/2472041/Thermi, an Almirall company, is launching Arvati, a next-generation 510K US Food and Drug Administration-cleared, true temperature-controlled radiofrequen
- New Guidelines Seek to Rein in Inappropriate Teen Plastic Surgerieshttps://modernaesthetics.com/news/new-guidelines-seek-to-rein-in-inappropriate-teen-plastic-surgeries/2472045/New teen plastic surgery guidelines call for age consideration, parental consent and other measures to improve upon the safety of these procedures. The guidelines are published in the September issue of Plastic and Reconstr
- Evolus Resubmits BLA for DWP-450 Ahead of Schedulehttps://modernaesthetics.com/news/evolus-resubmits-bla-for-dwp-450-ahead-of-schedule/2472049/Evolus has resubmitted its Biologics License Application (BLA) for its lead product candidate, DWP-450 (prabotulinumtoxinA), to the FDA. The resubmission follows the receipt of a Complete Response Letter (“CRL”) from the FDA in May 2018 which necessita
- Leading Plastic Surgery Groups Warn on the Risks of Brazilian Butt Liftshttps://modernaesthetics.com/news/leading-plastic-surgery-groups-warn-on-the-risks-of-brazilian-butt-lifts/2472050/Leading plastic surgery organizations are issuing a loud warning call about the risks associated with the popular Brazilian Butt Lift. “[The] procedure … has resulted in a mortality rate that is estimated to be as high as 1:3,000, greater than any other cosmetic surgery,&rdqu
- eRelevance Patient Engagement Survey: Opportunities and Shortfalls for Aesthetics Practiceshttps://modernaesthetics.com/news/erelevance-patient-engagement-survey-highlights-opportunities-for-aesthetics-practices/2472051/eRelevance Corporation, the leading provider of consumer engagement services for small- to medium-size businesses (SMBs) has released
- Bonti's Novel Neurotoxin Shows Promise in Early Study of Scar Reduction After Mohs Surgeryhttps://modernaesthetics.com/news/bontis-novel-neurotoxin-shows-promise-in-early-study-of-scar-reduction-after-mohs-surgery/2472052/Topline results from Bonti’s SHINE-1 Phase 2a clinical trial suggest that its novel neurotoxin is safe and likely effective for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical
- Most Women Think Their Hands Make Them Look Oldhttps://modernaesthetics.com/news/most-women-think-their-hands-make-them-look-old/2472058/Just shy of 80 percent of women ages 40 and older wish they could change the way their hands look, according to Nestlé Skin Health&rsquo